• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Does Drinking Coffee Reduce the Risk of Type 2 Diabetes in Women with a History of GDM?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Coffee consumption has been shown to reduce the risk of type 2 diabetes (T2D)
  • Yang et al. (American Journal of Clinical Nutrition, 2022) assessed whether greater habitual coffee consumption was associated with a lower risk of T2D among high-risk women with a history of gestational diabetes (GDM)

METHODS:

  • Prospective cohort study
    • NHS II (see ‘Learn More – Primary Sources’, below)
    • Between 1991 and 2017
  • Participants
    • Individuals with a history of GDM
  • Exposure
    • Self-reported consumption of caffeinated and decaffeinated coffee
  • Study design
    • Demographic, lifestyle factors including diet, and disease outcomes were collected every 2 to 4 years
    • Fasting blood samples were collected from 2012 to 2014 from a subset of participants free of diabetes to measure glucose metabolism biomarkers (HbA1c, insulin, C-peptide)
    • Multivariable Cox regression models were used to calculate adjusted hazard ratio (HR) and 95% CIs for the risk of T2D
    • The least squares mean of glucose metabolic biomarkers were calculated according to coffee consumption
  • Primary outcome
    • Type 2 diabetes

RESULTS:

  • 4522 participants
    • Developed T2D: 979 participants
  • Compared to consuming zero cups per day, caffeinated coffee consumption was inversely associated with the risk of T2D
    • ≤1 (nonzero) cups per day: aHR 0.91 (95% CI, 0.78 to 1.06)
    • 2 to 3 cups per day: aHR 0.83 (95% CI, 0.69 to 1.01)
    • ≥4 cups per day: aHR 0.46 (95% CI, 0.28 to 0.76)
    • Ptrend=0.004
  • Replacing 1 serving per day of sugar-sweetened beverage or artificially sweetened beverage with one cup of caffeinated coffee lowered the risk of T2D
    • Replacing sugar-sweetened beverage: Risk ratio (RR) 0.83 (95% CI, 0.75 to 0.93)
    • Replacing artificially sweetened beverage: RR 0.91 (95% CI, 0.84 to 0.99)
  • Greater caffeinated coffee consumption was associated with lower
    • Fasting insulin
    • C-peptide concentrations (Ptrend<0.05)
  • Decaffeinated coffee intake was not significantly related to T2D but was inversely associated with C-peptide concentrations (Ptrend=0.003)

CONCLUSION:

  • Women with a history of GDM who drank caffeinated coffee on a regular basis had a lowered risk of T2D and a more favorable metabolic profile

Learn More – Primary Sources:

Habitual coffee consumption and subsequent risk of type 2 diabetes in individuals with a history of gestational diabetes – a prospective study

Nurses’ Health Study (NHS I) and Nurses’ Health Study II (NHS II)

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free >>

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Sweetened or Unsweetened: Does Coffee Consumption Reduce Risk of Mortality?
The Intersection of Coffee and Genetics: Is There an Impact on Mortality?
Is Daily Tea Drinking Associated with Lower Mortality?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site